HK Media's Jiangsu Tour: How Two Yangzhou Equipment Manufacturers Stand Out on the Global Stage

The Hong Kong media delegation visited Jiangsu FAMSUN Intelligent Technology Co., Ltd. and Myande Group Co., Ltd. in Yangzhou on March 26. Executives from the two manufacturers of agri-machinery & grain processing equipment introduced their respective corporation characteristics, noting that their businesses now span more than 80 countries and regions worldwide.

Jiangsu FAMSUN Intelligent Technology Co., Ltd., Photo by Bastille Post

Despite logistical disruptions caused by the ongoing situation in the Middle East, both corporations stated that the impact remains manageable and that they continue to expand their overseas markets, leveraging their comprehensive solution capabilities and rapid delivery advantages.

Two Months, Not Eight: FAMSUN's Speed Advantage Over Europe and America

Mr. Zhou Zhiqiang, Vice President of FAMSUN, stated that the corporation started with feed equipment and has since expanded horizontally into grain storage, livestock farming, and agriculture. Its products are now exported to over 140 countries and regions, with overseas business accounting for more than 55% of total revenue.

Mr. Zhou Zhiqiang, Vice President of FAMSUN, Photo by Bastille Post

He emphasized that the corporation's core competitiveness lies in its "full-solution" approach — not only providing equipment, but also assisting clients with financing and solving operational problems. While European and American competitors typically require 8 to 1o months for delivery, FAMSUN can reduce the timeline to just two to three months.

FAMSUN's products, Photo by Bastille Post

"When clients encounter difficulties, we would find ways for solutions, help them overcome their problems, gain their trust, and even help them resolve some financial issues," Mr. Zhou said. "This is true comprehensive capability."

FAMSUN's exhibition hall, Photo by Bastille Post

The corporation's exhibition hall showcases large-scale warehousing projects FAMSUN has undertaken. Photo by Bastille Post

The corporation's exhibition hall showcases large-scale warehousing projects FAMSUN has undertaken, including the Smart Grain Silo project in Zimbabwe and the "Future Egypt" Grain Silo project in Egypt. The latter has a total storage capacity of approximately 500,000 tons. Abdel Fattah Saeed Hussein Khalil el-Sisi, the President of Egypt, once personally inspected the site and highly praised the project.

FAMSUN Smart Park: Welcome to the Future of Farming Equipment

FAMSUN Smart Park's workshop is built to international lighthouse factory standards, making it the world's first intelligent factory in the agricultural and livestock equipment field to meet this benchmark. The park houses a global project command center that displays real-time data on construction projects worldwide. AGV robots shuttle across the production lines transporting materials, while automatic spraying and automated warehousing are fully unmanned.

FAMSUN Smart Park, Photo by Bastille Post

FAMSUN Smart Park's workshop, Photo by Bastille Post

The corporation currently serves as the secretariat undertaking unit for the ISO/TC293 Technical Committee on Feed Machinery and the National Feed Machinery Standardization Technical Committee, giving it a direct voice in international standard setting.

Myande: Asia's No. 1 in Grease Pre-Impregnation Equipment

Founded in 2003 with only 40 to 50 employees, Myande set a goal of becoming a "respected global leader in its niche market" by its founder and stayed focused on the corporation's core business for over two decades without deviation.

The production workshop of Myande, Photo by Bastille Post

Mr. Li Xudong, Global Marketing Vice President of Myande, stated that the corporation holds approximately 30% global market share and over 80% domestic market share in the grease pre-impregnation equipment field, ranking first in Asia and among the top 2 globally. Its clients include the world's four major grain traders, like ADM, and leading domestic giants like COFCO. "We've spent over a decade building localized marketing channels," Mr. Li said. "Once we identify a business opportunity from a client, our success rate and prediction accuracy are extremely high."

Mr. Li Xudong, Global Marketing Vice President of Myande, Photo by Bastille Post

Regarding geopolitical disruptions, Mr. Li pointed out that the most direct impact of the Middle East situation on the corporation has been personnel movement — Dubai is a crucial transit point for travel between the Middle East, Europe, and South America. Sales and service personnel faced travel disruptions at the beginning of the conflict, but have since recovered quickly. He also noted that the Russia-Ukraine conflict has heightened concerns about food security, leading to increased investment in food processing equipment in Russian-speaking countries, which have now become one of Myande's largest market profit contributors.

Myande's scopes of business, Photo by Bastille Post

Myande's New Frontier: Solid-State Fermentation Equipment

In recent years, Myande has expanded its business into solid-state fermentation, developing fermentation equipment and cultivating beneficial bacteria to eliminate the need for antibiotics in feed production, improving food safety from the source.

Photo by Bastille Post

The corporation has also maintained a flag-raising ceremony for all employees on the first working day of every month for over 20 years without interruption. When introducing Myande's development history, the executive said: "For us, running a business is like adding water when there's too much flour, and adding flour when there's too much water. With accumulated capital, we expand production capacity. It's this persistence that has brought us to where we are today."

The innovation center of Myande, Photo by Bastille Post

The innovation center of Myande, Photo by Bastille Post

The photo wall documenting Myande's development history, Photo by Bastille Post

The Hong Kong media delegation visited Jiangsu Aidea Pharmaceutical Co., Ltd. on March 25. Ms. Liu Yan, the corporation's Board Secretary, introduced the latest commercial progress of the corporation's two Class 1 innovative anti-HIV drugs. Ms. Liu also stated that the corporation plans to list in Hong Kong in the long term, aiming to leverage the city's financing flexibility to support clinical trials in the U.S. and expansion into the African market.

Photo by Bastille Post

Photo by Bastille Post

From AIDS Fighter to STAR Market Listing: Aidea's Rise

Founded in Yangzhou in 2009, Aidea Pharmaceutical Co., Ltd., listed on the STAR Market in 2020, and remains the only corporation from Yangzhou currently listed on the exchange. According to Ms. Liu, the corporation's founder started the business in Guangzhou in the previous years. After selling Guangdong Techpool Biopharma Co., Ltd., the founder returned to the hometown of Yangzhou to establish Aidea Pharmaceutical Co., Ltd.

Ms. Liu Yan, the corporation's Board Secretary, Photo by Bastille Post

The corporation's English name, "Aidea," was jokingly interpreted by the media as "Aidea, the AIDS fighter" based on the similarity of Chinese pronunciation when the corporation first went public. "It seems destined that we would achieve something in this field," Ms. Liu said.

Ms. Liu Yan, the corporation's Board Secretary, Photo by Bastille Post

Filling the Gap, Doubling Revenue: Aidea's Two Innovative Drugs Deliver

China currently has four innovative oral anti-HIV drugs on the market, and Aidea Pharmaceutical owns two of them: Ainuovirine Tablets (Aibangde) and Ainuomiti Tablets (Fubangde). The former is the first domestically developed Class 1 oral anti-HIV drug, while the latter is the only domestically produced triple-combination drug, requiring just one tablet every 24 hours.

The drug products released by Aidea Pharmaceutical Co., Ltd., Photo by Bastille Post

The drug products released by Aidea Pharmaceutical Co., Ltd., Photo by Bastille Post

According to Ms. Liu, among the more than one million HIV patients in China, approximately 60–70% still use free generic drugs. However, the market penetration rate of innovative drugs continues to rise, and she predicts the overall market size will reach 11 billion RMB by 2027. She revealed that Aidea's HIV business revenue has doubled annually for nearly four years — soaring from just 33 million RMB in 2022 to nearly 300 million RMB in 2025.

The drug products released by Aidea Pharmaceutical Co., Ltd., Photo by Bastille Post

Aidea's Innovative HIV Drugs: Just 70 RMB per Patient

Ms. Liu specifically highlighted Fubangde as an example. The suggested monthly price is 724 RMB, but after medical insurance reimbursement, patients in some provinces actually pay as little as 70 RMB.

The drug products released by Aidea Pharmaceutical Co., Ltd., Photo by Bastille Post

She described how free generic drugs, while effective at suppressing the virus, can lead to long-term side effects such as insomnia, depression, and headaches. "Although lifespan has increased, the quality of life has severely declined," she said. In contrast, Aidea's innovative drugs offer significant advantages in safety and convenience. Relevant clinical data from the corporation has been published in top international journals.

The drug products released by Aidea Pharmaceutical Co., Ltd., Photo by Bastille Post

Accelerates U.S. Clinical Trials, Explores International Financing Channels

Regarding the R&D Pipeline, Ms. Liu highlighted ACC017, an integrase inhibitor comparable to Gilead's globally bestselling HIV drug. The product has entered Phase III clinical trials, and the corporation is currently in discussions with the U.S. FDA, with plans to launch U.S. clinical trials next year. The corporation has announced a refinancing plan of no more than 1.277 billion RMB, with the raised funds primarily allocated to clinical expenses and related R&D in the U.S. market.

Regarding a potential Hong Kong listing, Ms. Liu described it as a "future consideration", noting that the corporation's current A-share market capitalization stands at less than 10 billion RMB. Nevertheless, she believes Hong Kong offers distinct advantages in terms of international financing flexibility and overseas capital flow. "Hong Kong's refinancing is very flexible," she said. "A corporation can issue shares five or six times in a year, which is basically impossible in the A-share market."

Photo by Bastille Post

Photo by Bastille Post

Photo by Bastille Post

Photo by Bastille Post

Photo by Bastille Post

Photo by Bastille Post

Photo by Bastille Post